Apolipoprotein C-III: understanding an emerging cardiovascular risk factor

Area of Science:

• Cardiovascular Science
• Metabolic Disorders
• Lipoprotein Metabolism

Background:

• Metabolic syndrome, characterized by visceral obesity, insulin resistance, and dyslipidemia, is a growing global health concern.
• Dyslipidemia in metabolic syndrome significantly elevates cardiovascular disease (CVD) risk, primarily through hypertriglyceridemia and low HDL-cholesterol.
• Apolipoprotein C-III (ApoC-III) is a critical regulator of lipoprotein metabolism, strongly linked to hypertriglyceridemia and CVD progression.

Purpose of the Study:

• To elucidate the role of apolipoprotein C-III (ApoC-III) in the pathophysiology of metabolic syndrome and associated cardiovascular disease (CVD) risk.
• To explore the mechanisms by which ApoC-III influences triglyceride-rich lipoprotein (TRL) metabolism and hepatic uptake.
• To investigate the potential of targeting ApoC-III metabolism as a therapeutic strategy for managing dyslipidemia in metabolic syndrome.

Main Methods:

• Utilizing tracer methodology and mathematical modeling to understand the complex physiology and pathophysiology of lipoprotein metabolism.
• Analyzing the association between increased ApoC-III concentration and delayed triacylglycerol and TRL catabolism in metabolic syndrome.
• Examining the impact of existing therapies, such as PPAR agonists and statins, on ApoC-III transport.

Main Results:

• ApoC-III impairs the lipolysis of triglyceride-rich lipoproteins (TRLs) by inhibiting lipoprotein lipase and hinders hepatic TRL uptake.
• Increased hepatic production of very-low-density lipoprotein (VLDL)-ApoC-III in metabolic syndrome correlates with delayed triacylglycerol catabolism.
• Experimental evidence suggests ApoC-III may directly contribute to atherosclerosis development.

Conclusions:

• ApoC-III dysregulation is a key feature of metabolic syndrome, contributing to atherogenic dyslipidemia and CVD risk.
• Targeting ApoC-III metabolism presents a promising novel therapeutic avenue for managing dyslipidemia and reducing CVD risk in patients with metabolic syndrome.